New app aims to help liver disease patients abstain from alcohol

The study, published in the journal JHEP Reports, found that 57% of those using the AlcoChange app remained abstinent over a three month period, compared with just 22% of those who did not use the app regularly.

AlcoChange uses several behavioural change strategies, including a mobile phone-based breathalyser and personalised messages, to help patients abstain, including telling them how much money they will save by not buying alcohol to sending them pictures of loved ones and providing them solutions to overcome cravings. The breathalyser allows the patients to show their families and friends that they are sober, helping to build trust.

The trial resulted in fewer hospital admissions among the group using the app – even a year after they had stopped using it.

Dr Gautam Mehta, first author of the study from UCL Division of Medicine and the Royal Free Hospital, said: “This pilot study is very promising and if the results are replicated in larger trials, we think that this could pave the way to using digital tools to provide high-intensity alcohol abstinence support in people’s own homes.

“It has the potential to be particularly useful, given that few patients receive medication or talking therapy to help maintain abstinence. Alcohol-related liver disease is an increasing health problem worldwide, with a huge cost to health systems.

“In the group who were using the app, there were fewer hospital readmissions, which ultimately could lead to fewer people dying of this disease, which worldwide kills an estimated three million people every year.”

Professor Rajiv Jalan, senior author of the study from UCL Division of Medicine and the Royal Free Hospital, said: “It is exciting to see the positive results of this study. Harnessing digital technology has the potential to revolutionise the management of patients with liver disease as it can be delivered continuously at home, reducing the need for patients having to travel and impacting dramatically on costs of healthcare delivery.”

AlcoChange was developed by Cyberliver Ltd, a UCL spin-out company co-founded by Professor Jalan.

A larger randomised nationwide study funded by the National Institute for Health and Care Research (NIHR) has now been launched to establish which patients are likely to benefit the most and evaluate its cost-effectiveness.

Susan (not her real name), 50, from north London, was one of the original participants in the initial AlcoChange study. For Susan an abusive relationship had led to depression and anxiety, which she had sought to numb by drinking.

She said: “I’d ended up as an inpatient undergoing a detox at the Royal Free Hospital because I’d been drinking up to three bottles of wine a day and frankly I jumped at the chance to take part in the study.

“What really helped me was when I clicked on the app to report I was having a craving a picture of my daughter came up which reinforced for me why I wanted to stop drinking. I found it incredibly easy to use and there’s nothing like it out there which compares with it. I also loved the breathalyser part of it. It took a picture of you while you were using it and showed your score so you could prove you weren’t drinking to others.”

Susan said although she was still struggling with her relationship with alcohol, she was now getting support from a charity for her addiction.

She added: “I didn’t start drinking again until after the trial was over. Personally, it was a great experience for me and to be honest I was gutted when the trial finished. I think for someone like me who is confident using their smartphone it was good to have something so accessible and interactive.”

Links

• Dr Gautam Mehta's academic profile
• Professor Rajiv Jalan’s academic profile
• UCL Institute for Liver and Digestive Health
• UCL Division of Medicine
• UCL Faculty of Medical Sciences

Image

• Credit: OntheRunPhoto on iStock.

Media contact

Matt Midgley

Tel: +44 (0)20 3108 6995

Email: m.midgley [at] ucl.ac.uk